Kieren J. Mather

Endocrinology

975 W Walnut St
Indianapolis, IN 46202

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 143 publications

Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis.

Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis.

Journal: Journal of the Endocrine Society

Published: April 20, 2026

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.

Journal: Diabetes, obesity & metabolism

Published: April 06, 2026

Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

Journal: The lancet. Diabetes & endocrinology

Published: April 02, 2026

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Journal: Lancet (London, England)

Published: September 29, 2025

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.

Journal: Molecular metabolism

Published: September 25, 2025

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

Journal: Diabetes, obesity & metabolism

Published: September 09, 2025

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

Journal: Molecular metabolism

Published: August 18, 2025

Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.

Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.

Journal: Diabetes care

Published: June 03, 2025

Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.

Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: May 16, 2025

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

Journal: Diabetes, obesity & metabolism

Published: April 24, 2025

A Post-Hoc Analysis of Depressive Disorders in Patients with Type 2 Diabetes.

A Post-Hoc Analysis of Depressive Disorders in Patients with Type 2 Diabetes.

Journal: Healthcare (Basel, Switzerland)

Published: March 30, 2025

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.

Journal: Cardiovascular diabetology

Published: March 05, 2025

Showing 1-12 of 143

Last Updated: 09/26/2026